1. Multimorbidity and HIV co-morbid with other chronic conditions is an increasingly important issue around the world. 2. The generalizability of the findings of this study is a very substantial limitation. The study arises from 1 health facility in Malawi-and is not representative of the public sector health care delivery system, which is utilized by a large proportion of patients in Malawi, other parts of Africa, and around the world. 3. Definition of "non-integrated care," dependent on relative timing of medication purchase/refill, is problematic. It is quite conceivable that a patient was prescribed both BP meds and ART at an "integrated" visit, but purchased the BP meds at a different time due to liquidity concerns/issues. 4. Unclear if "refill visits" refers to refills of both ART and BP meds? Or just for BP meds? 5. The category of "zero total hypertension care-seeking expenditure/costs" is unclear. What is the definition? How compared to the other categories? 6. Is "travel time" per visit? Or cumulative? Unclear 7. Results seem to indicate that costs of medications in integrated care were more expensive (might be related to specific pricing scheme at the study location?), hence some individuals opted for non-integrated care and confronted other costs (travel, opportunity costs, etc). On balance, unclear the overall impact? Discussion section does not address this sufficiently. 8. Detailed information about price differences across different facilities is missing and is critical to understanding choices that patients made in terms of integrated vs. non-integrated care. 9. Relationship between Appendix 3 and Table 3 unclear. 10. Table 2 : would be preferable to present the refill of specific medications by integrated vs. non-integrated. Also, how do the refill patterns compare to the prescription patterns (those are not always aligned). 11. There are a few grammatical errors that can be corrected.
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GENERAL COMMENTS
The authors present a unique paper describing the pressing issue of how to address one of the key co-morbidities seen with HIV, hypertension. Despite using a cross-sectional study design, they were to describe numerous key findings within this population which largely center around the importance of cost as a factor impacting the uptake of integrated care.
Overall comments
-Some of the strengths about this being the first study of patient experiences are a bit strong. There are several studies from SSA that have looked at this specific topic. There was also an entire special issue in AIDS which touched upon this issue. AIDS 2018; 32(Supplement 1):S5-S20 This, however, might be the first example from Malawi so you might want to soften that strength
Methods
Can you provide more details on what hypertension care looks like in this center and whether partners in hope is a public or private sector facility? What are the all the average costs for care (i.e. consultation, meds (cost for hctz since 90% were on that), labs if available etc) for hypertension? Is it safe to assume that the availability of hypertension medications was reliable and always available. within the Partners of Hope center? Was there any payment for participation in the study? I'm interested by the finding of refills at the same time as the HIV visit. One common phenomenon we have seen in Kenya is that patients will refill a month supply of medications if they have to pay for it even though their next appointment might not be for three months. Do you have any insight on this observation. It might help to discuss the typical frequency for HIV visits and HTN visits even if you have anecdotal information on that.
Results
Can you help me understand why you separated the populations by male and female is there something I should be noting as a difference between the two populations. I think it is fine to leave table 1 the way it is but if there is a relevant inference I should be making from this delineation then make it clear. If there isn't, then you might just be able to illustrate the contribution of male and female populations as a row in the table rather than a column. The authors note that 80% had uncontrolled BP despite being on medication. From the data or in the discussion could authors indicate or hypothesise as to why this is so high? Amongst those not controlled, was there a difference between duration on antihypertensive and therapy line (authors only mention difference by sex). For example, is it that so many have high BP because they have not been referred to 2L+ or only recently started or because they are not responding? It seems that the survey provides information on who is on what line (at least when mapping to guidelines, eg at least 25.1% are on TL when looking at use of enalapril, so about 28% on SL (53-25%) and ~40% on FL (90-53%)). Could authors describe the line in the result section or else mention in discussion that it would be interesting to look at referral to subsequent lines and understand link with being uncontrolled. Other papers have also found low control low in Malawi (e.g. Ambebir et al 2019 -Systematic review of hypertension, diabetes burden, risk factors and interventions for prevention and control in Malawi). In the discussion can authors compare their results (and reasons for failure to control) to other settings.
When describing antihypertensive medication ( Table 2 and text) could authors indicating which drugs are which class eg in the text (e.g. calcium channel blockers (e.g. amlodipine, etc) or in Table 2 for easy referencing when reading the results and non-experts.
Malawi guidelines are HCTZ is first-line, HCTZ+Amlodipine is second-line and HCTZ + Amliodipine + Enalapril is third-line (it reads as though 2L is only calcium blockers). Can authors clarify and add reference for guidelines.
Authors should (where possible) provide explanation for the trends they find either with sub-analysis or in discussion. For example, a) low control (see above), b) why were those using antihypertensives longer less likely to refill in integrated manner. Is this due to the timing of when integration took place (ie those not using integrated refill started taking medication before it was possible to get refills at ART clinic?). Was this difference significant and could author report p-value? c) Regarding zero total expenditure is the fact that it is 6% in both groups due to the fact that diagnosis is mostly free in ART clinics but that antihypertensives are more likely to be free in non-integrated care?
The section on costs could benefit from being rewritten to make the results of the analysis more easily understandable. E.g. introduce term zero expenditure and clearly tease out the two key findings: zero expenditure higher in non-integrated and amongst those who do pay for medication higher in non-integrated due to additional marginal costs? This clear description of key results should also be made in abstract. At the moment abstract seems to say integrated care is more favourable but does not highlight zero expenditure being higher in non-integrated care model. In results authors seem to indicate that only 6% are free but it is unclear what the distinction of hypertension care (costs of diagnosis and treatment) between the two models in Malawi is (the extra information in backgroundcomment abovewill also help with this interpretation).
P-values should be stated where comparisons btw groups are made?
It is unclear if the authors mean that reasons for refilling in each location was only reported amongst the n=18 who filled in different location or amongst all respondents. It should definitely be reported amongst all respondents.
Discussion:In discussion could authors elaborate on generalisability of results (as they are based on only one clinic).
Using several sites could help to make results more generalizable, and are there any bias that could result in these findings from this study site?
Can authors refer to sample
Minor comments: -Keyword should include hypertension and/or antihypertensive (maybe instead of non-communicable diseases or one of the last 3 terms) -In results the last sentence of the 5th paragraph should be in preceding paragraph describing differences btw those seeking integrated care and not), while paragraph 5 describes costs.
-In the result section two full sentences are in brackets, error? -Could authors consider reporting difference by number of medication (last sentence of 5th paragraph of results […](data not shown) in appendix? -When citing the SA study in discussion (ref 40) it appears part of the sentence is missing. Do authors mean that addressing these barriers were estimated to only marginally improve outcomes?
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 1. The generalizability of the findings of this study is a very substantial limitation. The study arises from 1 health facility in Malawi-and is not representative of the public sector health care delivery system, which is utilized by a large proportion of patients in Malawi, other parts of Africa, and around the world. Thank you for noting this. We agree that this is a limitation of this studybut as it is one of the first to examine care-seeking costs for NCDs from a patient perspective in a low-income country, we hope that it nonetheless contributes to the literature. This study was done in an HIV clinic that serves a population very similar to HIV clinics throughout Malawi, where care for HIV treatment and HIV-related complications is free, but services for other co-morbidities require payment. We have reorganized our Limitations section so that this concern is highlighted up-front (p12).
2. Definition of "non-integrated care," dependent on relative timing of medication purchase/refill, is problematic. It is quite conceivable that a patient was prescribed both BP meds and ART at an "integrated" visit, but purchased the BP meds at a different time due to liquidity concerns/issues. We categorized care as "integrated" if the client reported refilling antihypertensive medications during their visit at Partners in Hope at the same time as receiving ART refills. Any one antihypertensive medication refill outside of Partners in Hope, or at Partners in Hope but not at the same time as an ART visit, caused that respondent to be classified as a "nonintegrated care" user. We agree that people who were offered "integrated care" could have opted for refilling their medicines elsewhere or later, due to financial or other constraints --and therefore a main goal of the paper was to describe these behaviors, and understand the reasons that may drive decisions about where and when to refill medications. We have updated the Methods to more clearly define our use of the "integrated" and "non-integrated care" terminology (p6).
3. Unclear if "refill visits" refers to refills of both ART and BP meds? Or just for BP meds?
We have clarified this (p6): it refers to visits for antihypertensive medications since these were the focus of this study.
4. The category of "zero total hypertension care-seeking expenditure/costs" is unclear. What is the definition? How compared to the other categories?
We have expanded our Methods section to specify how this was defined and operationalized (p6).
Is "travel time" per visit? Or cumulative? Unclear
We have clarified this (it is an annual [cumulative] measure) (p9).
6. Results seem to indicate that costs of medications in integrated care were more expensive (might be related to specific pricing scheme at the study location?), hence some individuals opted for non-integrated care and confronted other costs (travel, opportunity costs, etc). On balance, unclear the overall impact? Discussion section does not address this sufficiently. Certain medications were more expensive at Partners in Hope, and as we note, respondents cited cost as a main reason for refilling elsewhere. The results suggest that clients do not calculate or consider the "opportunity costs" of going elsewhere to find less expensive medications: as they seek to save money on medications, they may spend more money on transportation, time, and child care. We suspect some people may be unaware that this tradeoff is occurring, and a main conclusion of the study is to assist clients in recognizing the opportunity costs of opting out of buying medications in an "integrated" model. If integrated care actually saves clients' money despite slightly more expensive medication costs, this is a salient finding for people faced with these decisions. that is a key conclusion of the study. We have reorganized the Discussion so this point is highlighted up-front (p10).
7. Detailed information about price differences across different facilities is missing and is critical to understanding choices that patients made in terms of integrated vs. non-integrated care.
Our study was not a supply-side pricing study, and therefore we do not have these data available. We have added language about where medicines are available for free versus for a fee (p5). In our experience and as noted elsewhere in the literature, medication prices can fluctuate widely across sales outlets. A goal of this study was to learn about where clients go for less expensive medications (or where they perceive medications to be less expensive)as we have summarized in our Results.
8. Relationship between Appendix 3 and Table 3 unclear. Table 3 presents average (mean) values for annual care-seeking costs, and Appendix 3 presents median values for these same variables. We have updated Appendix 3 so the formatting more closely mirrors Table 3 , which we hope clarifies this point. 9. Table 2 : would be preferable to present the refill of specific medications by integrated vs. nonintegrated. Also, how do the refill patterns compare to the prescription patterns (those are not always aligned).
We have added two columns in Table 2 to show the distribution of medicines by integrated and non-integrated care users (p8).
10. There are a few grammatical errors that can be corrected. We have done a thorough re-review of this draft, and hope we have corrected all of the grammatical errors.
Reviewer: 2 11. Some of the strengths about this being the first study of patient experiences are a bit strong. There are several studies from SSA that have looked at this specific topic. There was also an entire special issue in AIDS which touched upon this issue. AIDS 2018; 32(Supplement 1):S5-S20 This, however, might be the first example from Malawi so you might want to soften that strength Thank you for noting this. We agree that there are several articles that have looked at patient experiences with integrated care, and have softened the language: this is, to the best of our knowledge, the first study to look at refill costs and experiences, from a patient perspective, for integrated HIV-NCD care. We have added citations to papers from this Supplement, as well as more recent articles on related topics (p10-11).
12. Can you provide more details on what hypertension care looks like in this center and whether partners in hope is a public or private sector facility? What are the all the average costs for care (i.e. consultation, meds (cost for hctz since 90% were on that), labs if available etc) for hypertension? Partners in Hope is a mission facility, and is part of the Christian Health Association of Malawi network of hospitals and health centers. Partners in Hope has both a "private" model outpatient clinic for those with health insurance and/or those who want to pay out of pocket for general medical care; and a "public" model free HIV clinic in which HIV care is provided for free (including care for HIV-associated complications) and HIV medications are provided for free. Respondents for this study were recruited from the latter patient population. As such, those in the "integrated care" model did not pay for consultations nor labs (although these are not routine, except annual viral loadbut if a provider is worried about an issue such as renal function, specific tests such as creatinine would be free to the client since this is considered part of HIV care). Therefore, the main costs to clients for NCD care at Partners in Hope are for medications. As noted above, we did not collect supply-size price databut, we have clarified details of what aspects of integrated care are offered for free (vs for a fee) at the study site (p5).
13. Is it safe to assume that the availability of hypertension medications was reliable and always available. within the Partners of Hope center? Thank you for this comment, we have added a clarification (p5).
Was there any payment for participation in the study?
We have added this on page 5.
15. I'm interested by the finding of refills at the same time as the HIV visit. One common phenomenon we have seen in Kenya is that patients will refill a month supply of medications if they have to pay for it even though their next appointment might not be for three months. Do you have any insight on this observation. It might help to discuss the typical frequency for HIV visits and HTN visits even if you have anecdotal information on that. In Malawi during the time period of this study, most stable HIV clients were given a threemonth supply of ART. It is possible that these clients were also prescribed a three-month supply of antihypertensive medications, but chose to only pay for one month due to financial constraints. Unfortunately, we are not able to determine how often this happened for the population in our study because we only asked whether they filled ART and HTN meds at the same visit. We did not ask more nuanced questions about whether they limited their HTN refill amount. This is a limitation of our study and we have added this information in the limitations section (p12).
16. Can you help me understand why you separated the populations by male and female is there something I should be noting as a difference between the two populations. I think it is fine to leave table 1 the way it is but if there is a relevant inference I should be making from this delineation then make it clear. If there isn't, then you might just be able to illustrate the contribution of male and female populations as a row in the table rather than a column. Thank you for noting this. We agree that this is not the most informative stratification for the data; we have reconfigured Tables 1 and 2 accordingly. 17. Table 3 -in row 3, you mention annual visits, I'm assuming this means number of visits in a year. Might be good to just slightly clarify the language. We have adjusted this language (changed "annual" to "each year").
18. Table 3 -Can you show the differences in bp control between the two groups In our revision to Table 1 , this is now included.
Reviewer: 3 19. Abstract: The abstract should provide some additional information, eg a) provide information on the health facility (i.e. that they specifically screen and provide clinical management for HTN during ART visitsi.e. is integrated), b) key results as per result section ie include that non-integrated has more zero medication expenditure, c) explanation about why people do not use integrated care if it is cheaper.
We have very limited space to add more detail to the abstract due to a word limit of 300 words. We removed some non-essential text to accommodate this reviewer's request, and hope the editors agree with the changes we made (p2).
Background:
In background (or methods) can authors clarify that in HIV platforms blood pressure measurement (hypertension diagnosis) is free, while antihypertensives are charged? This will help with result interpretation. We have added this (p5).
Methods:
In method, authors should outline all areas of data collection. Currently reason for refill is only mentioned at end of results and in abstract. Method should fully describe the whole survey and overall methods. This should include how reason for refill was analysed and reported (see comment below). We have added this, thank you for noting its omission (p5-6).
22. Some information should be moved from result section to methods and only a brief reference made in result to remind reader, eg. A) definition of marginal costs. B) Full definition of zero total hypertension care-seeking expenditure, does it refer to all aspects except medication or including medication?
We have added discussion of this to Methods (p6).
Results:
In results, would authors be amenable to referring to how many of the patients had controlled BP versus elevated blood pressure in text (and in the Table 1) ?
We have included the % of participants with normal versus elevated blood pressure in the text and in Table 1. 24. The authors note that 80% had uncontrolled BP despite being on medication. From the data or in the discussion could authors indicate or hypothesise as to why this is so high? Amongst those not controlled, was there a difference between duration on antihypertensive and therapy line (authors only mention difference by sex). For example, is it that so many have high BP because they have not been referred to 2L+ or only recently started or because they are not responding? It seems that the survey provides information on who is on what line (at least when mapping to guidelines, eg at least 25.1% are on TL when looking at use of enalapril, so about 28% on SL (53-25%) and ~40% on FL (90-53%)). Could authors describe the line in the result section or else mention in discussion that it would be interesting to look at referral to subsequent lines and understand link with being uncontrolled. Other papers have also found low control low in Malawi (e.g. Ambebir et al 2019 -Systematic review of hypertension, diabetes burden, risk factors and interventions for prevention and control in Malawi). In the discussion can authors compare their results (and reasons for failure to control) to other settings. As this was a cross-sectional survey with data collected at a single time point, we would be reluctant to draw conclusions about long-term blood pressure control. We included the information about blood pressure in this paperdespite the overall focus on integrated versus non-integrated carebecause we felt it was important, but limited conclusions can be drawn from this one time point. Separately, we are analyzing data from an observational cohort, and in this future paper we hope to explore precisely this issue about antihypertensive medications, adherence, and blood pressure control over time. The need for further research on this issue has been added to the Discussion (p13).
25. When describing antihypertensive medication (Table 2 and text) could authors indicating which drugs are which class eg in the text (e.g. calcium channel blockers (e.g. amlodipine, etc) or in Table 2 for easy referencing when reading the results and non-experts. Thank you, we have added this to the text (p8).
26. Malawi guidelines are HCTZ is first-line, HCTZ+Amlodipine is second-line and HCTZ + Amliodipine + Enalapril is third-line (it reads as though 2L is only calcium blockers). Can authors clarify and add reference for guidelines. Thank you, we have clarified this and added the citation (p6).
27. Authors should (where possible) provide explanation for the trends they find either with subanalysis or in discussion. For example, a) low control (see above), b) why were those using antihypertensives longer less likely to refill in integrated manner. Is this due to the timing of when integration took place (ie those not using integrated refill started taking medication before it was possible to get refills at ART clinic?). Was this difference significant and could author report p-value? c) Regarding zero total expenditure is the fact that it is 6% in both groups due to the fact that diagnosis is mostly free in ART clinics but that antihypertensives are more likely to be free in non-integrated care?
We agree with the reviewer that the results raise interesting points for further exploration and studybut as noted above, we are hesitant to posit too many specific hypotheses based on these data from a single time point at one health facility. The reviewer's suggestion is a possible explanation but we do not know this without further (likely qualitative) study. We have clarified some points throughout that we hope respond to most of this reviewer's suggestion (including adding a p-value on the difference between duration on antihypertensive medications between groups, and more detail about what is free versus for-free at the study site).
28. The section on costs could benefit from being rewritten to make the results of the analysis more easily understandable. E.g. introduce term zero expenditure and clearly tease out the two key findings: zero expenditure higher in non-integrated and amongst those who do pay for medication higher in non-integrated due to additional marginal costs? This clear description of key results should also be made in abstract. At the moment abstract seems to say integrated care is more favourable but does not highlight zero expenditure being higher in non-integrated care model. In results authors seem to indicate that only 6% are free but it is unclear what the distinction of hypertension care (costs of diagnosis and treatment) between the two models in Malawi is (the extra information in backgroundcomment abovewill also help with this interpretation). We have reworked the presentation of cost data in the Results text, and hope it is now more clear. We also added a bit more specificity to the Abstract but we are very word-constrained.
29. P-values should be stated where comparisons btw groups are made? P-values are reported for comparisons throughout except in Table 2 where the sample size for all medications (besides the top 3) are very small.
30. It is unclear if the authors mean that reasons for refilling in each location was only reported amongst the n=18 who filled in different location or amongst all respondents. It should definitely be reported amongst all respondents. We have clarified this in Methods (p6) and the presentation of this finding in Results also specifies that the unit of analysis is the refill visit (not the person) so the 18 people with multiple locations contribute to each of those bars.
Discussion:
In discussion could authors elaborate on generalisability of results (as they are based on only one clinic). Using several sites could help to make results more generalizable, and are there any bias that could result in these findings from this study site?
We agree that the single-center nature of the study is a limitation. This study was conducted in an ART clinic that serves a general population very similar to those seen at other sites throughout Malawi. Care for HIV treatment and HIV-related complications is free at Partners in Hope, while care for other co-morbidities requires payment for services rendered. There may be important differences between HIV+ individuals in urban and rural settings (particularly in relation to where medications are available, and travel time to facilities offering free medications). At the time we began this study, very few ART clinics in Malawi provided truly integrated ART-HTN care, so a multi-site project would have been very challenging to design. It is an important limitation of the study, and we have emphasized this in the revised Limitations section of the manuscript (p12).
Can authors refer to sample
We do not understand this comment, but would be happy to address it if the reviewer can clarify their request.
Minor comments: Keyword should include hypertension and/or antihypertensive (maybe instead of non-communicable diseases or one of the last 3 terms)
We have added it.
34. In results the last sentence of the 5th paragraph should be in preceding paragraph describing differences btw those seeking integrated care and not), while paragraph 5 describes costs. We have reworked the Results section and this problem has been resolved.
35. In the result section two full sentences are in brackets, error?
We believe that the re-writing of Results has eliminated this problem. We have removed use of the phrase "marginal costs" as we feel it added confusion (page 9). We clarified the subheading title on page 9: "Total care-seeking costs (medication plus other)." We also added a sentence on page 6 to clarify this in Methods: "Costs are presented for each type of expenditure, and a total (which adds together all expenditures: medications, transport, lost wages, and food or childcare)."
In addition, authors could review the abstract, results and start of discussion to ensure the key results (which are interesting) are always thoroughly and carefully articulated. For example: in discussion when stating that non-integrated had higher cost due to marginal costs could also add that medication cost was same (Table 3) to contextualise We added a sentence to Discussion to note this (page 10): "More people in the nonintegrated care group reported zero expenditure on medicines, but among those who did pay, the annual cost of antihypertensive medications was not significantly different between the integrated care and non-integrated care groups."
in first paragraph of discussion authors state that patients "seemed to be optimizing the near-term "savings" of money and time by choosing the most convenient location and/or where the medication itself was least expensive." This is misleading in fact it is not cheaper. Instead authors could write: "patients who choose to refill in non-integrated manner do so due to the perceived reduced costs of medication" followed by the second part of the sentence 'in fact ...'
We have changed this sentence to read: "They report choosing the most convenient location and/or the location where they feel that the medication was least expensivebut, in fact, these patients experienced higher total annual costs (both direct and indirect)."
Conclusions do not relate to the findings -should this be updated?
We have rewritten the second half of Conclusions (pages 12-13) to read: "This success means that many countries are experiencing a double burden of disease among adults, and the HIV-focused vertical model may no longer be the most successful strategy for addressing diseases of aging and improving health outcomes in high-burden settings. This study finds high care-seeking costs for adults with hypertension and HIV in Malawi, and complex preferences for medication refill decisions. Integrated care is a promising approach for addressing comorbidities, but these findings suggest that co-locating services may not necessarily result in less economic burden for clients. Investments in NCDs are estimated to be cost-and life-saving,(56) so global health policy makers and financers, both external and domestic, should consider this a strategic priority, and consider approaches that incorporate patient preferences and experiences in order to maximize impact and ensure equity." VERSION 3 -REVIEW REVIEWER Mikaela Smit Imperial College London (UK) REVIEW RETURNED 18-Dec-2019
GENERAL COMMENTS
Thank you for taking the time and care to address all outstanding comments.
